Roth/MKM Starts CervoMed (CRVO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
H.C. Wainwright Starts CervoMed (CRVO) at Buy
December 5, 2024 6:05 AM ESTH.C. Wainwright analyst Raghuram Selvaraju initiates coverage on CervoMed (NASDAQ: CRVO) with a Buy rating and a price target of $42.00.
For an analyst ratings summary and ratings history on CervoMed click here. For more ratings news on CervoMed click here.
Shares of CervoMed closed at $9.70 yesterday.
... More